BioWorld - Sunday, February 15, 2026

BioWorld Science

April 22, 2021

View Archived Issues

Enrollment begins in phase I/II study of etrumadenant in metastatic colorectal cancer

Read More

Brain-penetrant ALK inhibitor NUV-655 active against treatment-resistant mutations

Read More

Phase I trials planned for new PARP1/2 inhibitor RP-12146

Read More

AP-101 appears to be safe and well tolerated in phase I study in ALS patients

Read More

Aurigene CD73 inhibitor AU-21218 inhibits tumor growth in vivo

Read More

First patients dosed in SAVE 1 phase IIa study ATI-2173

Read More

FDA clears IND application for APB-102 as treatment of SOD1 ALS

Read More

FDA grants IND approval for Zofin in the treatment of osteoarthritis

Read More

Dosing starts in phase I study of AL-102 in combination with WVT-078 in patients with MM

Read More

AUT-00206 improves auditory information processing in patients with schizophrenia

Read More

Novartis and Gilead Sciences patent compounds for herpes virus infections

Read More

Nirogyone Therapeutics discloses MCT inhibitors

Read More

Boragen identifies new JAK inhibitors

Read More

Innovo Therapeutics synthesizes new immunomodulators

Read More

Sangamo Therapeutics presents new compounds for prion diseases

Read More

UCB-0599 shows safety in older individuals with PD with age-related comorbidities

Read More

Targeting the adenosine pathway for cancer immunotherapy

Read More

SAB-185 studied as part of ACTIV-2 trial for treatment of COVID-19

Read More

AN-3025: an anti-TNFR2 antibody for cancer immunotherapy

Read More

Valneva begins pivotal trial of COVID-19 vaccine candidate VLA-2001

Read More

Treatment begins in clinical trial of GNT-0004 gene therapy for Duchenne muscular dystrophy

Read More

Bharat reports second interim analysis of phase III study of Covaxin COVID-19 vaccine candidate

Read More

PCSK9 affects antitumor immunity

Read More